Synergistic antitumor efficacy of aspirin plus lenvatinib in hepatocellular carcinoma via regulating of diverse signaling pathways
It has been established that monotherapy yields limited efficacy in treating hepatocellular carcinoma (HCC), especially advanced HCC. Increasing evidence from preclinical studies and clinical trials indicates that combining multiple drugs can potentially refine treatment efficacy. Accordingly, it is...
Saved in:
| Published in | Cell death discovery Vol. 9; no. 1; pp. 416 - 11 |
|---|---|
| Main Authors | , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
London
Nature Publishing Group UK
16.11.2023
Springer Nature B.V Nature Publishing Group |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | It has been established that monotherapy yields limited efficacy in treating hepatocellular carcinoma (HCC), especially advanced HCC. Increasing evidence from preclinical studies and clinical trials indicates that combining multiple drugs can potentially refine treatment efficacy. Accordingly, it is crucial to explore more effective clinically feasible combination therapies to enhance the treatment outcomes of HCC patients. This study evaluated the antitumor efficacy and safety of combination therapy involving aspirin and lenvatinib in HCC. Through in vitro and in vivo assays, we demonstrated that this combination yielded stronger antitumor effects compared to lenvatinib or aspirin monotherapy. Furthermore, no significant adverse events were observed in an HCC mouse model during treatment. Mechanistic studies revealed that aspirin plus lenvatinib could target multiple oncogenes and tumor suppressors, affecting diverse signaling pathways in various biological processes conducive to antitumor effects. Overall, our findings suggest that aspirin plus lenvatinib could serve as a promising combination regimen to improve the therapeutic outcomes of HCC. |
|---|---|
| AbstractList | It has been established that monotherapy yields limited efficacy in treating hepatocellular carcinoma (HCC), especially advanced HCC. Increasing evidence from preclinical studies and clinical trials indicates that combining multiple drugs can potentially refine treatment efficacy. Accordingly, it is crucial to explore more effective clinically feasible combination therapies to enhance the treatment outcomes of HCC patients. This study evaluated the antitumor efficacy and safety of combination therapy involving aspirin and lenvatinib in HCC. Through in vitro and in vivo assays, we demonstrated that this combination yielded stronger antitumor effects compared to lenvatinib or aspirin monotherapy. Furthermore, no significant adverse events were observed in an HCC mouse model during treatment. Mechanistic studies revealed that aspirin plus lenvatinib could target multiple oncogenes and tumor suppressors, affecting diverse signaling pathways in various biological processes conducive to antitumor effects. Overall, our findings suggest that aspirin plus lenvatinib could serve as a promising combination regimen to improve the therapeutic outcomes of HCC.It has been established that monotherapy yields limited efficacy in treating hepatocellular carcinoma (HCC), especially advanced HCC. Increasing evidence from preclinical studies and clinical trials indicates that combining multiple drugs can potentially refine treatment efficacy. Accordingly, it is crucial to explore more effective clinically feasible combination therapies to enhance the treatment outcomes of HCC patients. This study evaluated the antitumor efficacy and safety of combination therapy involving aspirin and lenvatinib in HCC. Through in vitro and in vivo assays, we demonstrated that this combination yielded stronger antitumor effects compared to lenvatinib or aspirin monotherapy. Furthermore, no significant adverse events were observed in an HCC mouse model during treatment. Mechanistic studies revealed that aspirin plus lenvatinib could target multiple oncogenes and tumor suppressors, affecting diverse signaling pathways in various biological processes conducive to antitumor effects. Overall, our findings suggest that aspirin plus lenvatinib could serve as a promising combination regimen to improve the therapeutic outcomes of HCC. It has been established that monotherapy yields limited efficacy in treating hepatocellular carcinoma (HCC), especially advanced HCC. Increasing evidence from preclinical studies and clinical trials indicates that combining multiple drugs can potentially refine treatment efficacy. Accordingly, it is crucial to explore more effective clinically feasible combination therapies to enhance the treatment outcomes of HCC patients. This study evaluated the antitumor efficacy and safety of combination therapy involving aspirin and lenvatinib in HCC. Through in vitro and in vivo assays, we demonstrated that this combination yielded stronger antitumor effects compared to lenvatinib or aspirin monotherapy. Furthermore, no significant adverse events were observed in an HCC mouse model during treatment. Mechanistic studies revealed that aspirin plus lenvatinib could target multiple oncogenes and tumor suppressors, affecting diverse signaling pathways in various biological processes conducive to antitumor effects. Overall, our findings suggest that aspirin plus lenvatinib could serve as a promising combination regimen to improve the therapeutic outcomes of HCC. Abstract It has been established that monotherapy yields limited efficacy in treating hepatocellular carcinoma (HCC), especially advanced HCC. Increasing evidence from preclinical studies and clinical trials indicates that combining multiple drugs can potentially refine treatment efficacy. Accordingly, it is crucial to explore more effective clinically feasible combination therapies to enhance the treatment outcomes of HCC patients. This study evaluated the antitumor efficacy and safety of combination therapy involving aspirin and lenvatinib in HCC. Through in vitro and in vivo assays, we demonstrated that this combination yielded stronger antitumor effects compared to lenvatinib or aspirin monotherapy. Furthermore, no significant adverse events were observed in an HCC mouse model during treatment. Mechanistic studies revealed that aspirin plus lenvatinib could target multiple oncogenes and tumor suppressors, affecting diverse signaling pathways in various biological processes conducive to antitumor effects. Overall, our findings suggest that aspirin plus lenvatinib could serve as a promising combination regimen to improve the therapeutic outcomes of HCC. |
| ArticleNumber | 416 |
| Author | Sui, Xin Li, Rong Liu, Huanyi Yu, Haoyuan Liang, Jinliang Li, Xuejiao Yao, Jia Zheng, Jun Yan, Xijing Hu, Zhongying |
| Author_xml | – sequence: 1 givenname: Xijing surname: Yan fullname: Yan, Xijing organization: Department of Hepatic Surgery and Liver Transplantation Center, Third Affiliated Hospital of Sun Yat-sen University – sequence: 2 givenname: Haoyuan orcidid: 0000-0002-5567-8885 surname: Yu fullname: Yu, Haoyuan organization: Department of Hepatic Surgery and Liver Transplantation Center, Third Affiliated Hospital of Sun Yat-sen University – sequence: 3 givenname: Jinliang orcidid: 0000-0002-9386-0645 surname: Liang fullname: Liang, Jinliang organization: Guangdong Provincial Key Laboratory of Liver Disease Research, Third Affiliated Hospital of Sun Yat-sen University – sequence: 4 givenname: Zhongying orcidid: 0000-0002-6312-2940 surname: Hu fullname: Hu, Zhongying organization: Guangdong Provincial Key Laboratory of Liver Disease Research, Third Affiliated Hospital of Sun Yat-sen University – sequence: 5 givenname: Xuejiao orcidid: 0000-0003-4197-4509 surname: Li fullname: Li, Xuejiao organization: Guangdong Provincial Key Laboratory of Liver Disease Research, Third Affiliated Hospital of Sun Yat-sen University – sequence: 6 givenname: Huanyi orcidid: 0000-0001-7127-7179 surname: Liu fullname: Liu, Huanyi organization: Guangdong Provincial Key Laboratory of Liver Disease Research, Third Affiliated Hospital of Sun Yat-sen University – sequence: 7 givenname: Jia surname: Yao fullname: Yao, Jia organization: Department of Hepatic Surgery and Liver Transplantation Center, Third Affiliated Hospital of Sun Yat-sen University – sequence: 8 givenname: Xin surname: Sui fullname: Sui, Xin email: drsuixin@126.com organization: Surgical ICU, Third Affiliated Hospital of Sun Yat-sen University – sequence: 9 givenname: Jun orcidid: 0000-0002-4283-0403 surname: Zheng fullname: Zheng, Jun email: zhengj67@mail2.sysu.edu.cn organization: Department of Hepatic Surgery and Liver Transplantation Center, Third Affiliated Hospital of Sun Yat-sen University – sequence: 10 givenname: Rong orcidid: 0000-0003-4951-577X surname: Li fullname: Li, Rong email: lirong53@mail.sysu.edu.cn organization: Guangdong Provincial Key Laboratory of Liver Disease Research, Third Affiliated Hospital of Sun Yat-sen University |
| BookMark | eNp9kU1v3CAYhK0qkZom-QM5IfXSi1swGOxjFfUjUqQe2pzRa_zisPKCC_ZWvuaXl123apVDTqDRMyOYeVOc-eCxKG4Yfc8obz4kwURFS1rxkjIpRbm-Ki4qWjelUkye_Xd_XVyntKOUsloJ1fCL4un76jEOLs3OEPCzm5d9iAStdQbMSoIlkCYXnSfTuCQyoj_A7LzrSJYecYI5GBzHZYRIDETjfNgDOTggEYesZnY4pvTugDEhSW7wMB7FbH38BWu6Ks4tjAmv_5yXxcPnTz9uv5b3377c3X68L42Q1VwCb1vOuVBWUtmxvu5Z3xhBhewoVl3Pa9kJBkxIzntLsZWqb3mnrJCiZpXil8XdltsH2Okpuj3EVQdw-iSEOGiIuYYRNTM5wrStRdsJzmgjKShGWasAK85pznq3ZU0x_FwwzXrv0rEH8BiWpKumZUq0TIiMvn2G7sIScwcnKi9DG95kqtkoE0NKEa02bs7lBT9HcKNmVB-31tvWOm-tT1vrNVurZ9a_f3vRxDdTyrAfMP571Quu34abv-I |
| CitedBy_id | crossref_primary_10_62347_UJVP4361 crossref_primary_10_1016_j_celrep_2024_114812 crossref_primary_10_1016_j_ctarc_2025_100884 crossref_primary_10_1016_j_taap_2024_116906 |
| Cites_doi | 10.1158/0008-5472.CAN-21-0758 10.1002/hep.31921 10.1016/j.biomaterials.2021.121003 10.3390/ph14010036 10.1016/S2468-1253(21)00110-2 10.1158/1078-0432.CCR-17-0242 10.1007/s11912-017-0605-6 10.1038/bjc.2016.172 10.15403/jgld.2014.1121.264.hra 10.1056/NEJMoa1912035 10.3322/caac.21660 10.1007/s00535-019-01642-1 10.1038/s41572-020-00240-3 10.1126/science.1215327 10.1124/pr.58.3.10 10.1042/BSR20180854 10.1158/0008-5472.CAN-16-2400 10.1002/hep.32023 10.1038/s41569-020-0366-z 10.1016/j.bbcan.2020.188391 10.1056/NEJMoa1915745 10.1016/S0140-6736(18)30010-2 10.3390/cancers13071738 10.1038/nrc.2016.4 10.1053/j.gastro.2021.12.263 10.1016/j.intimp.2020.107281 10.1200/JCO.20.00808 10.3389/fphar.2020.00819 10.1002/ijc.31022 10.1002/med.21514 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2023 The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2023. The Author(s). |
| Copyright_xml | – notice: The Author(s) 2023 – notice: The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2023. The Author(s). |
| DBID | C6C AAYXX CITATION 3V. 7X7 7XB 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M7P PHGZM PHGZT PKEHL PQEST PQGLB PQQKQ PQUKI PRINS 7X8 DOA |
| DOI | 10.1038/s41420-023-01664-y |
| DatabaseName | Springer Nature OA Free Journals CrossRef ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences Health & Medical Collection (Alumni) Biological Science Database ProQuest Central Premium ProQuest One Academic ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest Natural Science Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Biological Science Collection ProQuest Central (New) ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest One Academic ProQuest Central (Alumni) ProQuest One Academic (New) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic ProQuest Central Student CrossRef |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 2058-7716 |
| EndPage | 11 |
| ExternalDocumentID | oai_doaj_org_article_1c3dfc99fefb4310860a710197ae2330 10_1038_s41420_023_01664_y |
| GrantInformation_xml | – fundername: Natural Science Foundation of Guangdong Province (Guangdong Natural Science Foundation) grantid: 2021A1515011156; 2021A1515012136 funderid: https://doi.org/10.13039/501100003453 – fundername: Guangzhou Basic and Applied Basic Research Foundation (202102020237);Guangzhou Basic and Applied Basic Research Project Co-funded by Municipal Schools (institutes) (SL2022A03J01381) – fundername: Major Talent Project Cultivation Plan Project (P02093) – fundername: National Natural Science Foundation of China (National Science Foundation of China) grantid: 81802897; 81901943; 81900597 funderid: https://doi.org/10.13039/501100001809 |
| GroupedDBID | 0R~ 3V. 53G 7X7 8FE 8FH 8FI 8FJ AAFWJ AAJSJ ABUWG ACSMW ADBBV ADRAZ AFKRA AFPKN AJTQC ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS BBNVY BCNDV BENPR BHPHI BPHCQ BVXVI C6C CCPQU EBLON EBS EMOBN FYUFA GROUPED_DOAJ HCIFZ HMCUK HYE LK8 M48 M7P M~E NAO OK1 PGMZT PQQKQ PROAC RNT RPM SNYQT UKHRP AASML AAYXX CITATION PHGZM PHGZT 7XB 8FK AARCD AZQEC DWQXO GNUQQ K9. PKEHL PQEST PQGLB PQUKI PRINS 7X8 PUEGO |
| ID | FETCH-LOGICAL-c462t-a39933347f606b1d5d1d8c4046b0e2bd356b41a14633df0e967d93b7f46451273 |
| IEDL.DBID | M48 |
| ISSN | 2058-7716 |
| IngestDate | Wed Aug 27 01:20:48 EDT 2025 Mon Jul 21 11:26:48 EDT 2025 Wed Aug 13 04:19:32 EDT 2025 Thu Apr 24 23:10:06 EDT 2025 Tue Jul 01 02:29:09 EDT 2025 Fri Feb 21 02:38:02 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c462t-a39933347f606b1d5d1d8c4046b0e2bd356b41a14633df0e967d93b7f46451273 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0001-7127-7179 0000-0002-9386-0645 0000-0003-4197-4509 0000-0002-5567-8885 0000-0002-6312-2940 0000-0003-4951-577X 0000-0002-4283-0403 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1038/s41420-023-01664-y |
| PQID | 2890580838 |
| PQPubID | 2041962 |
| PageCount | 11 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_1c3dfc99fefb4310860a710197ae2330 proquest_miscellaneous_2891749144 proquest_journals_2890580838 crossref_citationtrail_10_1038_s41420_023_01664_y crossref_primary_10_1038_s41420_023_01664_y springer_journals_10_1038_s41420_023_01664_y |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2023-11-16 |
| PublicationDateYYYYMMDD | 2023-11-16 |
| PublicationDate_xml | – month: 11 year: 2023 text: 2023-11-16 day: 16 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: New York |
| PublicationTitle | Cell death discovery |
| PublicationTitleAbbrev | Cell Death Discov |
| PublicationYear | 2023 |
| Publisher | Nature Publishing Group UK Springer Nature B.V Nature Publishing Group |
| Publisher_xml | – name: Nature Publishing Group UK – name: Springer Nature B.V – name: Nature Publishing Group |
| References | Li (CR16) 2017; 141 Mo, Luo, Huang, Wang, Huang (CR19) 2021; 91 Yamashita (CR25) 2020; 55 Dai (CR8) 2017; 23 Li (CR5) 2021; 276 Song (CR10) 2021; 8 Zhao, Zhang, Wang, Chen (CR17) 2020; 1874 Hawley (CR28) 2012; 336 Sung (CR1) 2021; 71 Ricciotti, Wangensteen, FitzGerald (CR14) 2021; 81 Finn (CR7) 2020; 38 Drew, Cao, Chan (CR11) 2016; 16 Facciorusso (CR18) 2021; 13 Chen, Holmes (CR12) 2017; 19 Ching, Reader, Fulton (CR31) 2020; 11 Lu, Gao, Yang, Hu, Li (CR6) 2022; 9 Simon (CR13) 2020; 382 Schjerning, McGettigan, Gislason (CR30) 2020; 17 Chou (CR33) 2006; 58 Henry (CR9) 2017; 77 Torrens (CR21) 2021; 74 Xie (CR15) 2018; 38 Hua, Zhang, Kong, Wang, Jiang (CR27) 2019; 39 Forner, Reig, Bruix (CR2) 2018; 391 Hatanaka, Naganuma, Kakizaki (CR20) 2021; 14 Bronger (CR32) 2016; 115 Szabo (CR26) 2017; 26 Llovet (CR24) 2021; 7 Vogel (CR4) 2021; 6 Forner, Colombo (CR3) 2022; 162 Zhang, Yang, Wang, Jiang (CR29) 2021; 13 Finn (CR23) 2020; 382 Yi (CR22) 2021; 74 WS Henry (1664_CR9) 2017; 77 Z Li (1664_CR5) 2021; 276 A Facciorusso (1664_CR18) 2021; 13 T Yamashita (1664_CR25) 2020; 55 ZY Xie (1664_CR15) 2018; 38 DC Mo (1664_CR19) 2021; 91 MM Ching (1664_CR31) 2020; 11 T Hatanaka (1664_CR20) 2021; 14 A Forner (1664_CR2) 2018; 391 IL Szabo (1664_CR26) 2017; 26 H Zhang (1664_CR29) 2021; 13 TC Chou (1664_CR33) 2006; 58 RS Finn (1664_CR23) 2020; 382 DA Drew (1664_CR11) 2016; 16 WY Chen (1664_CR12) 2017; 19 H Bronger (1664_CR32) 2016; 115 Y Lu (1664_CR6) 2022; 9 TG Simon (1664_CR13) 2020; 382 A Vogel (1664_CR4) 2021; 6 X Dai (1664_CR8) 2017; 23 H Sung (1664_CR1) 2021; 71 E Ricciotti (1664_CR14) 2021; 81 S Li (1664_CR16) 2017; 141 SA Hawley (1664_CR28) 2012; 336 RS Finn (1664_CR7) 2020; 38 JC Song (1664_CR10) 2021; 8 AM Schjerning (1664_CR30) 2020; 17 L Torrens (1664_CR21) 2021; 74 JM Llovet (1664_CR24) 2021; 7 H Hua (1664_CR27) 2019; 39 C Yi (1664_CR22) 2021; 74 A Forner (1664_CR3) 2022; 162 Y Zhao (1664_CR17) 2020; 1874 |
| References_xml | – volume: 81 start-page: 3751 year: 2021 end-page: 61 ident: CR14 article-title: Aspirin in hepatocellular carcinoma publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-21-0758 – volume: 74 start-page: 2544 year: 2021 end-page: 60 ident: CR22 article-title: Lenvatinib targets FGF receptor 4 to enhance antitumor immune response of anti-programmed cell death-1 in HCC publication-title: Hepatology. doi: 10.1002/hep.31921 – volume: 276 start-page: 121003 year: 2021 ident: CR5 article-title: Combined anti-hepatocellular carcinoma therapy inhibit drug-resistance and metastasis via targeting “substance P-hepatic stellate cells-hepatocellular carcinoma” axis publication-title: Biomaterials. doi: 10.1016/j.biomaterials.2021.121003 – volume: 14 start-page: 36 year: 2021 ident: CR20 article-title: Lenvatinib for hepatocellular carcinoma: a literature review publication-title: Pharmaceuticals. doi: 10.3390/ph14010036 – volume: 9 start-page: 69 year: 2022 ident: CR6 article-title: Nanomedicine-boosting icaritin-based immunotherapy of advanced hepatocellular carcinoma publication-title: Mil Med Res. – volume: 6 start-page: 649 year: 2021 end-page: 58 ident: CR4 article-title: Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial publication-title: Lancet Gastroenterol Hepatol. doi: 10.1016/S2468-1253(21)00110-2 – volume: 23 start-page: 6267 year: 2017 end-page: 78 ident: CR8 article-title: Aspirin inhibits cancer metastasis and angiogenesis via targeting heparanase publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-17-0242 – volume: 19 year: 2017 ident: CR12 article-title: Role of aspirin in breast cancer survival publication-title: Curr Oncol Rep. doi: 10.1007/s11912-017-0605-6 – volume: 115 start-page: 553 year: 2016 end-page: 63 ident: CR32 article-title: CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer publication-title: Br J Cancer doi: 10.1038/bjc.2016.172 – volume: 13 start-page: 2379 year: 2021 end-page: 87 ident: CR18 article-title: Lenvatinib versus sorafenib as first-line therapy of advanced hepatocellular carcinoma: a systematic review and meta-analysis publication-title: Am J Transl Res. – volume: 26 start-page: 395 year: 2017 end-page: 402 ident: CR26 article-title: PPIs prevent aspirin-induced gastrointestinal bleeding better than H2RAs. A systematic review and meta-analysis publication-title: J Gastrointest Liver Dis. doi: 10.15403/jgld.2014.1121.264.hra – volume: 382 start-page: 1018 year: 2020 end-page: 28 ident: CR13 article-title: Association of aspirin with hepatocellular carcinoma and liver-related mortality publication-title: N Engl J Med. doi: 10.1056/NEJMoa1912035 – volume: 71 start-page: 209 year: 2021 end-page: 49 ident: CR1 article-title: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries publication-title: CA Cancer J Clin. doi: 10.3322/caac.21660 – volume: 55 start-page: 113 year: 2020 end-page: 22 ident: CR25 article-title: REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset publication-title: J Gastroenterol. doi: 10.1007/s00535-019-01642-1 – volume: 7 start-page: 6 year: 2021 ident: CR24 article-title: Hepatocellular carcinoma publication-title: Nat Rev Dis Prim. doi: 10.1038/s41572-020-00240-3 – volume: 336 start-page: 918 year: 2012 end-page: 22 ident: CR28 article-title: The ancient drug salicylate directly activates AMP-activated protein kinase publication-title: Science. doi: 10.1126/science.1215327 – volume: 58 start-page: 621 year: 2006 end-page: 81 ident: CR33 article-title: Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies publication-title: Pharm Rev. doi: 10.1124/pr.58.3.10 – volume: 38 start-page: BSR20180854 year: 2018 ident: CR15 article-title: Aspirin enhances the sensitivity of hepatocellular carcinoma side population cells to doxorubicin via miR-491/ABCG2 publication-title: Biosci Rep. doi: 10.1042/BSR20180854 – volume: 77 start-page: 790 year: 2017 end-page: 801 ident: CR9 article-title: Aspirin suppresses growth in PI3K-mutant breast cancer by activating AMPK and inhibiting mTORC1 signaling publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-16-2400 – volume: 74 start-page: 2652 year: 2021 end-page: 69 ident: CR21 article-title: Immunomodulatory effects of lenvatinib plus anti-programmed cell death protein 1 in mice and rationale for patient enrichment in hepatocellular carcinoma publication-title: Hepatology. doi: 10.1002/hep.32023 – volume: 17 start-page: 574 year: 2020 end-page: 84 ident: CR30 article-title: Cardiovascular effects and safety of (non-aspirin) NSAIDs publication-title: Nat Rev Cardiol. doi: 10.1038/s41569-020-0366-z – volume: 1874 start-page: 188391 year: 2020 ident: CR17 article-title: Lenvatinib for hepatocellular carcinoma: from preclinical mechanisms to anti-cancer therapy publication-title: Biochim Biophys Acta Rev Cancer. doi: 10.1016/j.bbcan.2020.188391 – volume: 382 start-page: 1894 year: 2020 end-page: 905 ident: CR23 article-title: Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma publication-title: N Engl J Med. doi: 10.1056/NEJMoa1915745 – volume: 391 start-page: 1301 year: 2018 end-page: 14 ident: CR2 article-title: Hepatocellular carcinoma publication-title: Lancet. doi: 10.1016/S0140-6736(18)30010-2 – volume: 13 start-page: 1738 year: 2021 ident: CR29 article-title: Blockade of AMPK-mediated cAMP-PKA-CREB/ATF1 signaling synergizes with aspirin to inhibit hepatocellular carcinoma publication-title: Cancers. doi: 10.3390/cancers13071738 – volume: 8 start-page: 25 year: 2021 ident: CR10 article-title: Chinese expert consensus on diagnosis and treatment of trauma-induced hypercoagulopathy publication-title: Mil Med Res. – volume: 16 start-page: 173 year: 2016 end-page: 86 ident: CR11 article-title: Aspirin and colorectal cancer: the promise of precision chemoprevention publication-title: Nat Rev Cancer. doi: 10.1038/nrc.2016.4 – volume: 162 start-page: 1770 year: 2022 end-page: 72 ident: CR3 article-title: The maze of systemic therapy for hepatocellular carcinoma: did we find the compass? publication-title: Gastroenterology doi: 10.1053/j.gastro.2021.12.263 – volume: 91 start-page: 107281 year: 2021 ident: CR19 article-title: Safety and efficacy of pembrolizumab plus lenvatinib versus pembrolizumab and lenvatinib monotherapies in cancers: a systematic review publication-title: Int Immunopharmacol. doi: 10.1016/j.intimp.2020.107281 – volume: 38 start-page: 2960 year: 2020 end-page: 70 ident: CR7 article-title: Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma publication-title: J Clin Oncol doi: 10.1200/JCO.20.00808 – volume: 11 start-page: 819 year: 2020 ident: CR31 article-title: Eicosanoids in cancer: prostaglandin E2 receptor 4 in cancer therapeutics and immunotherapy publication-title: Front Pharmacol. doi: 10.3389/fphar.2020.00819 – volume: 141 start-page: 2571 year: 2017 end-page: 84 ident: CR16 article-title: By inhibiting PFKFB3, aspirin overcomes sorafenib resistance in hepatocellular carcinoma publication-title: Int J Cancer. doi: 10.1002/ijc.31022 – volume: 39 start-page: 114 year: 2019 end-page: 45 ident: CR27 article-title: Complex roles of the old drug aspirin in cancer chemoprevention and therapy publication-title: Medicinal Res Rev. doi: 10.1002/med.21514 – volume: 276 start-page: 121003 year: 2021 ident: 1664_CR5 publication-title: Biomaterials. doi: 10.1016/j.biomaterials.2021.121003 – volume: 23 start-page: 6267 year: 2017 ident: 1664_CR8 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-17-0242 – volume: 17 start-page: 574 year: 2020 ident: 1664_CR30 publication-title: Nat Rev Cardiol. doi: 10.1038/s41569-020-0366-z – volume: 13 start-page: 1738 year: 2021 ident: 1664_CR29 publication-title: Cancers. doi: 10.3390/cancers13071738 – volume: 39 start-page: 114 year: 2019 ident: 1664_CR27 publication-title: Medicinal Res Rev. doi: 10.1002/med.21514 – volume: 1874 start-page: 188391 year: 2020 ident: 1664_CR17 publication-title: Biochim Biophys Acta Rev Cancer. doi: 10.1016/j.bbcan.2020.188391 – volume: 382 start-page: 1894 year: 2020 ident: 1664_CR23 publication-title: N Engl J Med. doi: 10.1056/NEJMoa1915745 – volume: 26 start-page: 395 year: 2017 ident: 1664_CR26 publication-title: J Gastrointest Liver Dis. doi: 10.15403/jgld.2014.1121.264.hra – volume: 38 start-page: 2960 year: 2020 ident: 1664_CR7 publication-title: J Clin Oncol doi: 10.1200/JCO.20.00808 – volume: 6 start-page: 649 year: 2021 ident: 1664_CR4 publication-title: Lancet Gastroenterol Hepatol. doi: 10.1016/S2468-1253(21)00110-2 – volume: 77 start-page: 790 year: 2017 ident: 1664_CR9 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-16-2400 – volume: 91 start-page: 107281 year: 2021 ident: 1664_CR19 publication-title: Int Immunopharmacol. doi: 10.1016/j.intimp.2020.107281 – volume: 55 start-page: 113 year: 2020 ident: 1664_CR25 publication-title: J Gastroenterol. doi: 10.1007/s00535-019-01642-1 – volume: 382 start-page: 1018 year: 2020 ident: 1664_CR13 publication-title: N Engl J Med. doi: 10.1056/NEJMoa1912035 – volume: 162 start-page: 1770 year: 2022 ident: 1664_CR3 publication-title: Gastroenterology doi: 10.1053/j.gastro.2021.12.263 – volume: 7 start-page: 6 year: 2021 ident: 1664_CR24 publication-title: Nat Rev Dis Prim. doi: 10.1038/s41572-020-00240-3 – volume: 336 start-page: 918 year: 2012 ident: 1664_CR28 publication-title: Science. doi: 10.1126/science.1215327 – volume: 74 start-page: 2652 year: 2021 ident: 1664_CR21 publication-title: Hepatology. doi: 10.1002/hep.32023 – volume: 38 start-page: BSR20180854 year: 2018 ident: 1664_CR15 publication-title: Biosci Rep. doi: 10.1042/BSR20180854 – volume: 74 start-page: 2544 year: 2021 ident: 1664_CR22 publication-title: Hepatology. doi: 10.1002/hep.31921 – volume: 115 start-page: 553 year: 2016 ident: 1664_CR32 publication-title: Br J Cancer doi: 10.1038/bjc.2016.172 – volume: 19 year: 2017 ident: 1664_CR12 publication-title: Curr Oncol Rep. doi: 10.1007/s11912-017-0605-6 – volume: 81 start-page: 3751 year: 2021 ident: 1664_CR14 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-21-0758 – volume: 391 start-page: 1301 year: 2018 ident: 1664_CR2 publication-title: Lancet. doi: 10.1016/S0140-6736(18)30010-2 – volume: 8 start-page: 25 year: 2021 ident: 1664_CR10 publication-title: Mil Med Res. – volume: 9 start-page: 69 year: 2022 ident: 1664_CR6 publication-title: Mil Med Res. – volume: 16 start-page: 173 year: 2016 ident: 1664_CR11 publication-title: Nat Rev Cancer. doi: 10.1038/nrc.2016.4 – volume: 71 start-page: 209 year: 2021 ident: 1664_CR1 publication-title: CA Cancer J Clin. doi: 10.3322/caac.21660 – volume: 14 start-page: 36 year: 2021 ident: 1664_CR20 publication-title: Pharmaceuticals. doi: 10.3390/ph14010036 – volume: 11 start-page: 819 year: 2020 ident: 1664_CR31 publication-title: Front Pharmacol. doi: 10.3389/fphar.2020.00819 – volume: 58 start-page: 621 year: 2006 ident: 1664_CR33 publication-title: Pharm Rev. doi: 10.1124/pr.58.3.10 – volume: 141 start-page: 2571 year: 2017 ident: 1664_CR16 publication-title: Int J Cancer. doi: 10.1002/ijc.31022 – volume: 13 start-page: 2379 year: 2021 ident: 1664_CR18 publication-title: Am J Transl Res. |
| SSID | ssj0001574783 |
| Score | 2.2724538 |
| Snippet | It has been established that monotherapy yields limited efficacy in treating hepatocellular carcinoma (HCC), especially advanced HCC. Increasing evidence from... Abstract It has been established that monotherapy yields limited efficacy in treating hepatocellular carcinoma (HCC), especially advanced HCC. Increasing... |
| SourceID | doaj proquest crossref springer |
| SourceType | Open Website Aggregation Database Enrichment Source Index Database Publisher |
| StartPage | 416 |
| SubjectTerms | 631/67/1059/153 692/308/2778 Antitumor activity Apoptosis Aspirin Biochemistry Biomedical and Life Sciences Cell Biology Cell Cycle Analysis Clinical trials Hepatocellular carcinoma Life Sciences Liver cancer Signal transduction Stem Cells |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3LS-YwEA8iCF5kfbFdXYngTYtNk6btcVcUEfSigrcwaVL8QFv5Hkqv_uU7k_b7fMC6l4We0jSEzExnfpkXYwcWtLSyqmMosiJW1tkYSPAgr1NbCocWLGUjX17p81t1cZfdvWv1RTFhfXng_uCORSVdXZVl7WuLyg4t8ARQK4oyB58iGKe_L-q8d2Cqzw-muvByyJJJZHE8UUIhUkIVhehZaxV3HzRRKNj_wcr85BgN-ubsG1sbDEX-q9_gOlvyzQZb6VtHdpvs9bqjrL1QZpkD5drOHtsx91QRAqqOtzUHcqKPGv70MJtwVC50-dqMLMehe1RC05Yu7SkKlVfUUKhpH4E_j4CP-_b0uCtaxYXADc8p0AMod51TE-MX6CZb7Pbs9ObkPB76KcSV0uk0BjJGpFR5jajFCpc54YpKIUK2iU-tk5m2SgD-OyWeeeJLnbtS2rwm76dAO2ebLTdt478zbhPhsyS1tsQFFCgkSeazHDTiH8AnYmJ-tqYaio1Tz4sHE5zesjA9PQzSwwR6mC5ih4tvnvpSG1_O_k0kW8ykMtlhAJnHDMxj_sU8EdudE9wMsjsx5HrNCjRNi4jtL16j1BFVoPHtLMxBKFciGo3Y0ZxR3pb4-7Z__I9t77BV6npPKZFC77Ll6Xjmf6JtNLV7QQz-AIPQCrM priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3di9QwEA96IvgifmL1lAi-abmmSdP2SVQ8DkFf9GDfwuSjunDXrttdpa_-5c6k2V1O8KBPaTab3Ukyv5nJzI-xVxa0tNJ1OTRVkyvrbQ608aDuStsKjwiWspE_f9Fn5-rTolokh9uYrlXuzsR4UPvBkY_8hAJiVYOAoXm7-pkTaxRFVxOFxk12i0qX0aquF_XBx1JRdXiZcmUK2ZyMSii0l1BRoQ2ttcqnK_oolu2_gjX_CY9GrXN6j91NcJG_m-V7n90I_QN2eyaQnB6yP18nyt2LxZY5UMbt9nJY80B1IcBNfOg4UCh92fPVxXbkqGLIBdsvLcemH6iKNgO57ukuKndEK9QPl8B_LYGvZ5J6nBWN4uP1jcDpugdQBjsnKuPfMI2P2Pnpx28fzvLEqpA7pctNDgRJpFR1h7aLFb7ywjdOoZ1si1BaLyttlQA8QaX0XRFaXftW2rqjGKhAtPOYHfVDH54wbgsRqqK0tsUBFCioRRWqGjRaQYBPxsTuvzUulRwn5osLE0PfsjGzPAzKw0R5mCljr_efWc0FN67t_Z5Etu9JxbJjw7D-btLeM8LhD3Ft24XOIl5CI67AmSK2rSGUUhYZO94J3KQdPJrDesvYy_1r3HskFejDsI190KBr0SbN2JvdQjkM8f9pP73-G5-xO8RqTymPQh-zo816G54j9tnYF3GB_wXyvAKn priority: 102 providerName: ProQuest – databaseName: Springer Nature HAS Fully OA dbid: AAJSJ link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1La9wwEBZpQqGX0vRB3SZBhd5aU8t62D5uQ0NYaC9pIDcxsuR2IbHDPhJ8zS_vjGxvSGkLBZ9kWcgeyfONZuYbxt47MNLJukmh1GWqnHcp0MaDosldJTwiWMpG_vrNnJ6r-YW-2GH5lAsTg_YjpWX8TU_RYZ9WSig0dFDDoPFrjEr7R2yPqNpxbe_NZvOz-f3JiiZOeDlmyGSy_MPDD7RQJOt_gDB_c4pGXXPyjD0dQSKfDdPaZzuhfc4eD2Uj-xfs7qynjL1IscyB8mw3V92SB2KDgLrnXcOBHOiLll9fblYcFQsdvLYLx7HpJyqgdUcH9hSBymsqJtR2V8BvFsCXQ2l6nBWN4mPQRuAU5AGUt86pgPEt9KuX7Pzky_fj03SspZDWyuTrFAiISKmKBi0WJ7z2wpe1QuvYZSF3XmrjlAD8b0rpmyxUpvCVdEVDnk-BGOcV2227Nrxm3GUi6Cx3rsIBFCgohA66AIO2D-CVMDF9W1uPRONU7-LSRoe3LO0gD4vysFEetk_Yh-0z1wPNxj97fyaRbXsSRXZs6JY_7LhkrKjxReqqakLjECWh6ZbhTBHRFhByKbOEHUwCt-O-XVlyu-oSYWmZsHfb27jjSCrQhm4T-6AZV6ElmrCP00K5H-Lv037zf93fsidU254SH4U5YLvr5SYcIgJau6Nxyf8CXmICJA priority: 102 providerName: Springer Nature |
| Title | Synergistic antitumor efficacy of aspirin plus lenvatinib in hepatocellular carcinoma via regulating of diverse signaling pathways |
| URI | https://link.springer.com/article/10.1038/s41420-023-01664-y https://www.proquest.com/docview/2890580838 https://www.proquest.com/docview/2891749144 https://doaj.org/article/1c3dfc99fefb4310860a710197ae2330 |
| Volume | 9 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3da9swEBf9YLCXsU_mtQsa7G3zZlmyZD-MkYaWEmgZ6wJ5E5Itd4HU7pykm1_3l-9OtjM6usEgYJBlIft0ud9Pp7sj5LU1kluel6FJkzQUtrChQcUzqoxtxgpAsBiNfHYuT2diOk_mO2Qod9R_wNWd1A7rSc2a5bsf39qPoPAfupDx9P1KMAEkCKwPEGMpRdjukn2wTAorGpz1cL-LGsZs8eh0jiOYmQKu0MfR3D3MLVvlU_rfwqF_uE69RTp5SB70UJKOO9k_IjuuekzudcUl2yfk50WLcX0-ETM1GI27uaob6jBnhMlbWpfUoJt9UdHr5WZFwfzg9my1sBSavoKZWte4rY_nVGmOJYeq-srQm4WhTVfAHmaFoxT-aIejeBTEYHQ7xTLH3027ekpmJ8dfJqdhX3EhzIWM16FBuMK5UCXwGsuKpGBFmgvg0DZysS14Iq1gBv5dOS_KyGVSFRm3qkT_KAMk9IzsVXXlnhNqI-aSKLY2gwGEEUaxxCXKSGBIBn4BYcO31XmfjhyrYiy1d4vzVHfy0CAP7eWh24C82T5z3SXj-GfvIxTZticm0vYNdXOpe73ULIcXybOsdKUFLAUEL4KZAu5VxsWcRwE5HASuh8Wp0TmbpABe04C82t4GvUSpmMrVG98HyF4GfDUgb4eF8nuIv0_7xX-95AG5H-OKxYOJ8pDsrZuNewkwaW1HZFfN1Yjsj8fTiylcj47PP32G1omcjPzWw8hrxy98hhG4 |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKEYJLxVMNLWAkOEHUOHac5IAQr2pLHxdaaW_Gjp1lpTZZNrtUufKD-I3MOMmuikRvlXJKHMfxjD0znsdHyCujJTe8KEOdJVkojDWhxoWn0zI2ObOgwWI28vGJHJ2Jr-NkvEH-DLkwGFY57Il-o7Z1gWfke-gQSzJQGLL3s58hokahd3WA0OjY4tC1l2CyNe8OPgN9X8fx_pfTT6OwRxUICyHjRahRJHMu0hJ0d8NsYpnNCgF2oolcbCxPpBFMww7CuS0jl8vU5tykJfoAGUh76PcWuQ2CN0JjLx2n6zOdBKvR8z43J-LZXiOYAPsMBCPY7FKKsL0i_zxMwBXd9h93rJdy-_fJVq-e0g8dPz0gG656SO50gJXtI_L7W4u5gr64M9WY4bu8qOfUYR0KXbS0LqlG1_20orPzZUNBpOGRbzU1FG79ANG3qNFVgLGvtEAYo6q-0PTXVNO5m3gksWqCvVgfLuIohpdozJinCJ18qdvmMTm7kfl-QjarunLbhJqIuSSKjcmhA6GFTlniklRLsLo0XAFhw9yqoi9xjkgb58q72nmmOnoooIfy9FBtQN6s3pl1BT6ubf0RSbZqicW5_Y16PlH9WlesgB8p8rx0pUE2yWQEIwVdOtUu5jwKyO5AcNXvGI1a83dAXq4ew1pHqujK1UvfBgzIHGzggLwdGGXdxf-H_fT6L74gd0enx0fq6ODkcIfci5FdMdJR7pLNxXzpnoHetTDPPbNT8v2mV9dfZUw9Xg |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwED-NTiBeEJ8iMMBI8ATR4tj5ekCIsVUbg2oCJu3NsxOnVNqS0rRMeeXP4q_jzk1aDYm9TepT6jhO7s53P98XwCujY2FEXvo6jVJfmsL4mgRPJ2VoMl6gBUvZyF9G8f6x_HQSnWzAnz4XhsIq-z3RbdRFndMZ-TY5xKIUDYZ0u-zCIo52h--nP33qIEWe1r6dxpJFDm17gfCteXewi7R-HYbDve8f9_2uw4Cfyzic-5rUsxAyKdGON7yICl6kuUTMaAIbmkJEsZFc424iRFEGNouTIhMmKckfyFHz47w3YDMhVDSAzZ290dHX9QlPRLXpRZepE-DCG8klojVUk4jg41j67SVt6JoGXLJ0_3HOOp03vAt3OmOVfVhy1z3YsNV9uLlsX9k-gN_fWsocdKWemaZ838V5PWOWqlLovGV1yTQ58icVm54tGoYKjg6Aq4lheOkHKsJ5TY4DioRlOTU1qupzzX5NNJvZsesrVo1plsIFj1hGwSaa8ucZNVK-0G3zEI6v5Ys_gkFVV_YxMBNwGwWhMRlOILXUCY9slOgYMZjGnwe8_7Yq7wqeU9-NM-Uc7yJVS3oopIdy9FCtB29W90yX5T6uHL1DJFuNpFLd7kI9G6tO8hXP8UXyLCttadBaQwgZ4ErRsk60DYUIPNjqCa66_aNRa2734OXqb5R8ooqubL1wYxBOZoiIPXjbM8p6iv8v-8nVT3wBt1Cy1OeD0eFTuB0St1LYY7wFg_lsYZ-hETY3zztuZ3B63QL2F7mWQvk |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Synergistic+antitumor+efficacy+of+aspirin+plus+lenvatinib+in+hepatocellular+carcinoma+via+regulating+of+diverse+signaling+pathways&rft.jtitle=Cell+death+discovery&rft.au=Yan%2C+Xijing&rft.au=Yu%2C+Haoyuan&rft.au=Liang%2C+Jinliang&rft.au=Hu%2C+Zhongying&rft.date=2023-11-16&rft.issn=2058-7716&rft.eissn=2058-7716&rft.volume=9&rft.issue=1&rft_id=info:doi/10.1038%2Fs41420-023-01664-y&rft.externalDBID=n%2Fa&rft.externalDocID=10_1038_s41420_023_01664_y |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2058-7716&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2058-7716&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2058-7716&client=summon |